The current study assessed whether neuromelanin sensitive MRI (NM-MRI) is a potential biomarker for treatment resistance (TR) in first episode schizophrenia patients. NM-MRI is a novel MRI sequence, which indirectly measures dopamine synthesis. Twenty-three first episodes schizophrenia patients underwent a NM-MRI scan, treatment response was determined during follow-up. Standardized and manual segmentation protocols of the NM-MRI data were used and compared. Both segmentation protocols showed significantly lower NM-MRI signal in TR compared to responders. These findings demonstrate the potential of NM-MRI as biomarker. The predictive value of NM-MRI for TR and optimal segmentation method still require further investigation
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords